Asian Agribusiness Consulting

译文：

我们最近在香港与勃林格殷格翰公司的高级人员-中国动物健康副总裁Stephan Lange和中国业务发展经理Xu Lin进行了会谈。

勃林格殷格翰（BI）是全球最大的家族型动保企业，主要产品包括疫苗和药品方面。勃林格在美国、德国及中国都拥有大型的研发实验室，为养猪业提供了新疫苗和其他现代技术产品。勃林格致力于为全球的养猪业带来新技术和创新产品，如PRRS，PCV和回肠炎疫苗，它们都在亚洲和全球取得了显著成效。然而勃林格及其他规模较大的跨国动保公司在中国所占的市场份额相当低，仅占总市场份额的10% 。2016年，1843家中国动保公司占据90%的市场份额，其中有101家为疫苗公司。

当被问及亚洲养猪业的未来趋势时，Stephan和Xu表示中国的产业正在经历一场向大型农场整合的重大转变，其中许多公司现在正从上海和北京等传统密集型地区迁移到中国的中部和北部地区。他们预测，在未来的10年内，世界前十大猪肉生产公司中有8家将位于中国境内，但是中国猪业的快速增长也带来了弊端，农场需要更多专业的以及训练有素的技术经理对操作细节进行管理监督。

他们意识到中国乃至亚洲养猪业的需求正从治疗产品转向预防产品，例如疫苗的广泛使用。他们注意到随着疫苗使用量的增加也会带来一些难题，比如疫苗从生产商到使用终端这一过程中存在不同的运输方式。同时也发现由于标准研究及检测工具的限制性，这些新型疫苗的有效性可能会受到影响，比如对照动物实验和血清学实验。

他们觉得像勃林格这样的公司，与中国养猪行业从业人员进行互动，交流和沟通是一个非常重要的趋势。他们越来越多地使用数字技术，如微信和其他数字论坛，例如利用pig333.cn平台提供有关动物健康和营养方面的专业数据和信息。勃林格正在对数字基础设施进行重大投资，以保持与养猪业及其从业人员之间的密切联系。目前，中国1,843动物保健企业在销售和绩效方面的数据非常有限，所以新的数字技术可以为行业提供一个更有效的市场研究方法。

原文：

We chatted recently in Hong Kong SAR withsenior people in the BoehringerIngelheim Company. We met with Stephan Lange, VicePresident for Animal Health in China and Xu Lin, Business Development Managerfor China.

BoehringerIngelheim(BI) is the largest family-ownedmulti-national company operating globally in animal health products, including vaccines and pharmaceuticals. Boehringer has large Research and Development laboratories in the USA, Germany and China, developing new vaccines and other modern technology products for the pig industry. The Boehringer has a strong tradition of bringing new and innovative products with great benefits to the global pig farming industry, such as its PRRS, PCV and ileitis vaccines, many of which are Asian and global success stories.Inside China however, the proportion of the market taken by Boehringerand other large multi-national companies is still quite low, at only around 10 % of the total market share. In 2016, the 90% of the market share is taken up by the total of 1,843 Chinese animal health companies, of which 101 are vaccine companies.

When asked about likely future trends for the pig industry in Asia, Stephan and Xu indicated that Boehringer sees the major shifts in the Chinese industry towards consolidation into larger farm enter prises.Many of these companies are now moving away from the traditional pig-denselocations around Shanghai and Beijing, towards locations in central and northern China. They predicted that within 10 years, 8 out of the top 10 pig production companies in the world will be located inside China.This rapid growth in the Chinese pig industry has created its own problems, with a need for management oversight of the operational details by more new andwell-trained technical managers on these farms.

They also see shifts in Chinese and Asian pig industry away from the rapeutic products, towards products aimed at prevention,such as more vaccine usage. They do note some on-going problems in this increased usage of vaccines in the Chinese pig industry, in terms of variable methods for delivery of vaccines from the manufacturer to the end usage in pigs.They also note the limited usage of standard research and diagnostic tools inthe Chinese industry, such as controlled animal trials and serology, which mayimpactthe usefulness of these new vaccines.

They also see a major trend in the way that companies like Boehringer interact and engage and inform people in the pig industry in China. They increasingly use digital technology such as WeChat andother digital forums, like pig333.cn, to provide strong data and information onanimal health and nutrition. Boehringer is making major investments in digital infrastructure to keep a close and direct connection to the pig industry andits people. There is currently only limited data on the sales and performance of the 1,843 Chinese animal health companies, so the new digital technology can offer people in the Chinese industry a useful method to develop market research. 

来源：Dr Steven McOrist （Pig333译）